Inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase by small molecule kinase inhibitors has evolved as a critical therapeutic strategy in non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.